The estimated Net Worth of Lifesciences Ii, L.P.Clarus... is at least $1.8 Million dollars as of 17 September 2018. Lifesciences Clarus owns over 85,823 units of Nanostring Technologies Inc stock worth over $424,993 and over the last 11 years Lifesciences sold NSTG stock worth over $1,372,310.
Lifesciences has made over 4 trades of the Nanostring Technologies Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Lifesciences sold 85,823 units of NSTG stock worth $1,372,310 on 17 September 2018.
The largest trade Lifesciences's ever made was buying 750,000 units of Nanostring Technologies Inc stock on 1 July 2013 worth over $7,500,000. On average, Lifesciences trades about 158,921 units every 190 days since 2013. As of 17 September 2018 Lifesciences still owns at least 4,036,025 units of Nanostring Technologies Inc stock.
You can see the complete history of Lifesciences Clarus stock trades at the bottom of the page.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus..., and Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: